• Warning: sizeof(): Parameter must be an array or an object that implements Countable in /home/certerra/public_html/wp-content/plugins/revslider/includes/output.class.php on line 4074
    HOME ABOUT SERVICES CONTACT
    © 2019 Certerra Inc.
  • Certerra has developed a unique whole-brain assay to screen drugs for neuropsychiatric and neurological disorders.
    Our difference
    Whole-brain Pharmacomapping equals better CNS drug discovery.
  • We aim to radically improve predictability from preclinical studies to clinical trials.
    Certerra's drug-screening method, called "pharmacomapping", combines cutting-edge brain imaging and sophisticated statistical analyses to quantify drug-evoked brain activation at cellular resolution in animal models.
    Delineating
    For any given drug, Certerra's process generates a map of whole-brain drug-evoked activation (or inhibition) in the animal model i.e., a whole-brain map “Pharmacomap™”.
    Focusing
    Certerra offers pharmacomapping as a CRO to a broad spectrum of pharmaceutical companies developing treatments for neurodevelopmental, psychiatric, and neurodegenerative disorders.
  • Our central hypothesis is that the effects a drug has are largely determined by which neurons it activates. Thus, we assert that CNS clinical trial unpredictability is in large part due to the lack of methods for mapping these relationships. We have bridged this gap by developing an automated Pharmacomap platform that allows us to visualize and then quantify drug-evoked brain activation at single-neuron resolution.
    Why Pharmacomapping?
    Our services
  • Our Services Include:
    Pharmacomapping Level I
    Drug-evoked brainwide c-fos mapping in naive mice, acute or chronic protocols.
    Pharmacomapping Level II
    Computational comparisons to a proprietary Clinical Pharmacomap Library of FDA-approved drugs.
    Pharmacomapping Level III
    Brainwide c-fos mapping in conjunction with disease-relevant mouse behaviors.
    Alzheimer’s mouse models
    Brainwide mapping of beta amyloid or other AD pathology.
    Pharmacomapping in Alzheimer’s mouse models
    Brainwide c-fos mapping in conjunction with beta amyloid mapping.
    Custom assays
    Possibility to develop custom assays with a broad range of IHC-compatible antibodies.
  • Get in Touch
    Certerra, Inc.
    Broad Hollow Bioscience Park
    3 Bioscience Park Drive
    Farmingdale, NY 11735
    +1 631 227 5040
    info@certerra.us